ly high expression of c-Myc in glioma cancer stem cells is 1229652-21-4 web essential for their cell cycle regulation suggest that the growth of these cells may also require c-Myc activity. As demonstrated by growth curve assays, the total number of control CD133+ cells increased roughly six or seven fold over five days, whereas CD133+ cells depleted of c-Myc did not increase or decreased in number. Conversely, growth of the CD1332 population was only moderately attenuated with c-Myc knockdown. These results suggest that c-Myc preferentially contributes to sustained growth of tumor initiating cells. Loss of c-Myc induces apoptosis in glioma cancer stem cells c-Myc regulates cell cycle progression and proliferation of glioma cancer stem cells c-Myc plays a key role in regulating cellular proliferation by controlling the expression of cell cycle proteins. To interrogate the Myc Regulates Cancer Stem Cell 3 Myc Regulates Cancer Stem Cell ic or pro-apoptotic role of c-Myc in glioma cancer stem cells, we quantified apoptotic cell populations following knockdown of c-Myc. Annexin V staining revealed that depletion of c-Myc induced apoptosis in CD133+ glioma cells, whereas the control CD133+ cells contained a minimal apoptotic population. In contrast, the CD1332 population had only background staining of Annexin V regardless of c-Myc levels. Consistent with these data, the combined caspase 3/7 activity was elevated in CD133+ cells following c-Myc knockdown, but not in matched CD1332 cells. Taken together, these data suggest that 20171952 c-Myc is a survival factor for glioma cancer stem cells. Loss of c-Myc impairs neurosphere formation by glioma cancer stem cells Sharing certain key characteristics of normal stem cells, cancer stem cells are capable of self-renewal, which allows sustained maintenance of this subpopulation and expansion of the whole tumor. Serial neurosphere formation assay has been utilized as a surrogate of the self-renewal capacity of neural stem cells, and was recently employed in the brain tumor stem cells. In primary neurosphere formation assays, approximately 15% of control CD133+ cells formed neurospheres, whereas very few spheres were formed by cells depleted of c-Myc. Neurospheres developed in 100% of wells in the control group when plated at a density of 100 cells/well and in 8085% wells when plated at 10 cells/well. In contrast, neurospheres were formed by cells depleted of c-Myc expression in only 10% or 30% of wells when plated at a density of 100 cells/ well, while no spheres were found when these cells were plated at 10 cells/well. Of note, neurospheres formed by cells with reduced cMyc expression were markedly smaller than the spheres formed by the control cells and merely met the minimal criteria to be scored in our experiments. Lack of neurospheres formed by glioma cancer stem cells depleted of c-Myc suggests impaired selfrenewal. However, assessing secondary neurosphere formation was precluded because very few spheres were generated in the knockdown 
groups in the primary assay and the neurospheres had limited viability. These studies therefore could not definitely determine if c-Myc expression is required for self-renewal of glioma cancer stem cells. However, it 15771452 is expected that self-renewal of glioma cancer stem cells is inhibited by knockdown of c-Myc, based on our observations that glioma cancer stem cells failed to proliferate and underwent apoptosis upon knockdown of c-Myc. Knockdown of c-Myc inhibits the tumorigenic potential